版本:
中国

BRIEF-Enanta announces eight weeks of treatment with Abbvie's investigational drug achieved high SVR rates in challenging-to-treat genotype 3 chronic HCV patients

April 21 Enanta Pharmaceuticals Inc

* Enanta announces eight weeks of treatment with Abbvie's investigational, pan-genotypic, ribavirin-free HCV regimen of glecaprevir/pibrentasvir (g/p) achieved high SVR rates in challenging-to-treat genotype 3 chronic HCV patients

* Enanta - 95 percent patients with genotype 3 chronic hepatitis c virus , without cirrhosis, new to treatment achieved svr(12) with 8 weeks of treatment

* Enanta Pharmaceuticals Inc says in endurance-3 study, no patients who received 8 weeks of g/p discontinued treatment due to adverse events Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐